Registry for patients with relapsed and refractory hepatoblastoma
Official title: Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Hepatic Tumors Research Consortium Initiative
Run by Children's Hospital Medical Center, Cincinnati · NCT05556642 · Data updated 2026-11-12
This study is trying to gather information from patients with relapsed or hard-to-treat hepatoblastoma to better understand the disease and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Children's Hospital Medical Center, Cincinnati Academic / other |
| Locations | 1 site (Cincinnati, Ohio) |
| Status | Recruiting |
| Started | September 7, 2022 |
| Main results expected | September 1, 2032 |
| Study ends | September 1, 2040 |
| Registry record updated | March 18, 2026 |
| Trial ID | NCT05556642 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients of any age with a suspected or confirmed diagnosis of relapsed or refractory hepatoblastoma, as well as those under 6 years with Hepatocellular Malignant Neoplasm- Not Otherwise Specified.
✕Probably not a fit
Patients who are deceased or do not have a suspected or confirmed diagnosis of rrHBL will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to collect and analyze clinical, demographic, and pathological data from patients diagnosed with relapsed or refractory hepatoblastoma (rrHBL). It will gather biological specimens and imaging data to enhance understanding of the disease's biology and treatment options. Patients will be identified through existing registries, clinician referrals, or direct family contact. The collected data will be securely stored and may facilitate future research on tumor modeling and drug testing.
Why it matters
Potential benefit: If successful, this initiative could lead to improved understanding and treatment options for patients with relapsed and refractory hepatoblastoma.
How similar studies have gone: While there is limited data on similar registries for rrHBL, the approach of collecting comprehensive clinical and biological data has shown promise in other cancer research initiatives.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients of any age with a suspected diagnosis (per treating oncologist/surgeon) or confirmed diagnosis of a rrHBL and all patients with Hepatocellular Malignant Neoplasm- Not Otherwise Specified (HCN-NOS) who are \<6 years of age at the time of initial diagnosis * To allow for tumor modelling to be performed with fresh tissue from these cases, patients with suspected rrHBL are eligible to enroll on study * Unless the patient is deceased, all patients and/or one parent or legal guardian must provide written informed consent as well as HIPAA/release of information consent Exclusion Criteria: * None
Where it's running
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States Recruiting
Study contacts
- Study coordinator: rrHBL Registry
- Email: rrHBLRegistry@cchmc.org
- Phone: 844-722-8774
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Onivyde combined with talazoparib or temozolomide for children and young adults with recurrent solid tumors and Ewing sarcoma
This will test whether adding talazoparib or temozolomide to Onivyde helps children and young adults whose solid tumors or Ewing sarcoma have come back.
-
Tegavivint treatment for recurrent or refractory solid tumors in children
This study tests if a new intravenous medication called tegavivint can help children with tough-to-treat solid tumors, like Ewing sarcoma and desmoid tumors, by finding the right dose and seeing how well it works.
-
Allogeneic HCT for Refractory sJIA in Children and Young Adults
This study tests whether donor blood-forming cell transplantation can help children and young adults with difficult-to-treat systemic JIA, including those with lung involvement.
-
Proton MRI of Musculoskeletal and Lung Health
This study tests MRI techniques to take clearer pictures of the lungs in healthy people and those with lung, muscle, or bone conditions.
-
See how well the lungs distribute dissolved xenon gas during MRI in HSCT patients and others
This study tests a special MRI method using hyperpolarized xenon gas to visualize how gas and dissolved xenon move through the lungs in people who have HSCT, respiratory issues, or are healthy controls.
-
Semaglutide for teens with autism and obesity
This 6-month, two-arm study tests whether semaglutide can help reduce BMI in adolescents 12-18 with autism and obesity, alongside lifestyle counseling.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.